Pacific Biosciences of California Inc [NASDAQ: PACB] stock went on an upward path that rose over 2.14% on Monday, amounting to a one-week price increase of more than 33.23%. The company report on November 9, 2023 at 4:05 PM that PacBio to Present at Upcoming Investor Conferences.
PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences:.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 16, 2023, at 2:00 PM ET in New York, NY.
Over the last 12 months, PACB stock dropped by -19.29%. The one-year Pacific Biosciences of California Inc stock forecast points to a potential upside of 28.5. The average equity rating for PACB stock is currently 1.58, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $2.29 billion, with 267.44 million shares outstanding and 255.64 million shares in the current float. Compared to the average trading volume of 4.60M shares, PACB stock reached a trading volume of 6012821 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Pacific Biosciences of California Inc [PACB]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PACB shares is $12.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PACB stock is a recommendation set at 1.58. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for Pacific Biosciences of California Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 17, 2023.
The Average True Range (ATR) for Pacific Biosciences of California Inc is set at 0.56, with the Price to Sales ratio for PACB stock in the period of the last 12 months amounting to 13.54. The Price to Book ratio for the last quarter was 2.90, with the Price to Cash per share for the same quarter was set at 2.87.
PACB Stock Performance Analysis:
Pacific Biosciences of California Inc [PACB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 33.23. With this latest performance, PACB shares gained by 16.10% in over the last four-week period, additionally sinking by -34.30% over the last 6 months – not to mention a drop of -19.29% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PACB stock in for the last two-week period is set at 62.19, with the RSI for the last a single of trading hit 70.64, and the three-weeks RSI is set at 56.19 for Pacific Biosciences of California Inc [PACB]. The present Moving Average for the last 50 days of trading for this stock 8.04, while it was recorded at 7.92 for the last single week of trading, and 10.57 for the last 200 days.
Insight into Pacific Biosciences of California Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Pacific Biosciences of California Inc [PACB] shares currently have an operating margin of -237.58 and a Gross Margin at +38.08. Pacific Biosciences of California Inc’s Net Margin is presently recorded at -244.92.
Return on Total Capital for PACB is now -18.70, given the latest momentum, and Return on Invested Capital for the company is -19.40. Return on Equity for this stock declined to -46.42, with Return on Assets sitting at -16.65. When it comes to the capital structure of this company, Pacific Biosciences of California Inc [PACB] has a Total Debt to Total Equity ratio set at 168.59. Additionally, PACB Total Debt to Total Capital is recorded at 62.77, with Total Debt to Total Assets ending up at 53.70. Long-Term Debt to Equity for the company is recorded at 166.68, with the Long-Term Debt to Total Capital now at 62.06.
Reflecting on the efficiency of the workforce at the company, Pacific Biosciences of California Inc [PACB] managed to generate an average of -$408,645 per employee. Receivables Turnover for the company is 5.96 with a Total Asset Turnover recorded at a value of 0.07.Pacific Biosciences of California Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.43 and a Current Ratio set at 4.80.
PACB Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PACB. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pacific Biosciences of California Inc go to -1.00%.
Pacific Biosciences of California Inc [PACB] Institutonal Ownership Details
The top three institutional holders of PACB stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in PACB stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in PACB stock with ownership which is approximately 5.7994%.
